{"ticker": {"uuid": "051d55ab-f98a-4daa-9748-1b2383269173", "symbol": "TENX", "name": "Tenax Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "FMR LLC's Strategic Acquisition of Tenax Therapeutics Inc Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNnA0dXg0RjhtXzV3bEljWHJ4UW1jMkVaYzdzQjY3OEMwZFdnZnJDRnZaSjJFQ2JCUlpNaG5MUmplRTdhSmlZd01zT3Fjaml4LWVWNFlmZjRtclNYa2dhb09uNmNjZmpwLWJfV1NaOUNfbUFZcDNKVVNtWXd1NlZwSHVHU0FuaHRtdHVqenVHVzM4T0dReVlMMmlsaS1tVEVqSjNEdHRDbEl5X1V3Q1NZamFpQlI?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T03:48:59+00:00", "published_display": "15 Jul 2026 03:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tenax Therapeutics Inc For: 14 July By Investing.com", "summary": "This article reports on a Form 4 filing for Tenax Therapeutics Inc. dated July 14. It highlights the stock symbol TENX, which experienced a -2.63% change, and was published by Investing.com.", "url": "https://za.investing.com/news/stock-market-news/form-4-tenax-therapeutics-inc-for-14-july-93CH-4369080", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T00:11:48", "published_display": "15 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (TENX) CEO exercises options, adds 8,719 shares", "summary": "Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026, acquiring 8,719 common shares. These shares were purchased at exercise prices of $5.94 and $3.549 per share, with the aggregate exercise price paid in cash. Following these transact", "url": "https://www.stocktitan.net/sec-filings/TENX/form-4-tenax-therapeutics-inc-insider-trading-activity-2a1ba5559b93.html", "source_name": "Stock Titan", "published_at": "2026-07-14T23:11:48", "published_display": "14 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(TENX) as a Liquidity Pulse for Institutional Tactics", "summary": "An AI model analysis by Stock Traders Daily indicates a strong overweight bias for Tenax Therapeutics Inc. (NASDAQ: TENX) due to strong sentiment across all horizons and a mid-channel oscillation pattern. The analysis highlights an exceptional 89.3:1 risk-reward setup, targeting ", "url": "https://news.stocktradersdaily.com/news_release/8/TENX_as_a_Liquidity_Pulse_for_Institutional_Tactics_071326050001_1783976401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T16:41:36", "published_display": "13 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FMR LLC reports 3.94M-share holding in Tenax Therapeutics (TENX)", "summary": "FMR LLC has reported a 14.9% stake in Tenax Therapeutics (TENX), owning 3,942,373 shares of common stock as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The filing also notes sole dispositive power over these shares and re", "url": "https://www.stocktitan.net/sec-filings/TENX/schedule-13g-tenax-therapeutics-inc-passive-investment-disclosure-5-2b7f77a60e68.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:39:36", "published_display": "08 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "The article focuses on the enterprise value to EBITDA forward for Tenax Therapeutics, Inc. (NASDAQ: TENX). It presents a financial metric from TradingView, indicating a key valuation ratio for the company without providing specific numerical data. The content primarily serves as ", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T23:11:00", "published_display": "07 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "This page from TradingView provides financial information for Tenax Therapeutics, Inc. (NASDAQ: TENX), specifically focusing on its price to earnings forward. The content indicates market and financial data, but the core numerical values are not displayed in this excerpt.", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:11:06", "published_display": "07 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Raises Target Price to $35", "summary": "LifeSci Capital has maintained its \"Buy\" rating for Tenax Therapeutics (TENX.US) and increased its target price from $27 to $35. Analyst Gaurav Maini, who has a 100% success rate and a 31.8% average return over the past year, made this adjustment. This information is provided by ", "url": "https://www.moomoo.com/news/post/72517777/lifesci-capital-maintains-tenax-therapeutics-tenxus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-06T12:41:29", "published_display": "06 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "This article displays financial data for Tenax Therapeutics, Inc. (NASDAQ: TENX), specifically focusing on its \"Price to sales forward\" metric. The content provides a snapshot of the company's financials and general market information through a TradingView interface.", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:41:27", "published_display": "06 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUTBjWWQtREtieFBiTWJZSERmOVNzYmVIRjI5Yk41dkU0TktWd0FHX2NkS3kydEMxSkF5eFc5WDVxR3hfdC1UVWtYaHhvdGVSbmRvemxRZnY2NU1QSjVKdmlNVnUzVjNMWEZmN1pJNkJVV2d1dDRvWGJ3c2VuT3c0TlZ2ZVJ2VWdYTnBDTzN5dDZOQjVJWmp1aDZuSE54YmFfcS1XNmFJQTFpa3d4cjAwNGRR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "The article provides a title indicating an analysis of Tenax Therapeutics, Inc.'s enterprise value to EBIT forward. However, the content primarily consists of navigation links, market data disclaimers, and website information from TradingView, rather than a substantive financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:11:39", "published_display": "06 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tenax Therapeutics, Inc. \u2013 LS:A3EVQN", "summary": "This page provides financial data on Tenax Therapeutics, Inc. (A3EVQN), specifically focusing on its price-to-sales forward ratio. The content indicates that the market was closed at the time of viewing, with no trades reported. It also details the various data providers and copy", "url": "https://www.tradingview.com/symbols/LS-A3EVQN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T18:10:35", "published_display": "05 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Tenax Therapeutics announced inducement option awards on July 1, 2026, to three new non-executive employees in various roles, granting them non-qualified stock options to purchase 160,000 shares. These awards, approved by the Compensation Committee, serve as material inducements ", "url": "https://finance.yahoo.com/healthcare/articles/tenax-therapeutics-announces-inducement-grants-200500596.html?.tsrc=rss", "source_name": "Market source", "published_at": "2026-07-03T08:41:29", "published_display": "03 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Is Maintained at Buy by Chardan Capital", "summary": "Chardan Capital has reiterated its Buy rating on Tenax Therapeutics (NASDAQ: TENX). The article does not provide a price target or an updated analysis, only confirming the maintenance of the rating.", "url": "https://www.moomoo.com/news/post/72402119/tenax-therapeutics-is-maintained-at-buy-by-chardan-capital?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T19:10:53", "published_display": "02 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026", "summary": "Tenax Therapeutics (Nasdaq: TENX) has announced that results from its Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich. The company expects to report topline LEVEL result", "url": "https://investingnews.com/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-data-at-esc-congress-2026/", "source_name": "Investing News Network", "published_at": "2026-07-02T16:11:10", "published_display": "02 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Late-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial data", "summary": "Tenax Therapeutics (TENX) announced that results from its Phase 3 LEVEL clinical trial for TNX-103 in pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) will be presented at the European Society of Cardiology Congress 2026 as a Late-Breaking Clini", "url": "https://www.stocktitan.net/sec-filings/TENX/8-k-tenax-therapeutics-inc-reports-material-event-3dd8bcf66d9d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:09:39", "published_display": "02 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc. (TENX) announced that the data report from one of its pivotal clinical trials has been selected as a late-breaking presentation at the 2026 European Society of Cardiology Congress.", "summary": "Tenax Therapeutics, Inc. (TENX) announced that a data report from one of its pivotal clinical trials has been selected as a late-breaking presentation at the 2026 European Society of Cardiology Congress. This selection indicates international recognition of the company's progress", "url": "https://www.bitget.com/amp/news/detail/12560605487149", "source_name": "Bitget", "published_at": "2026-07-02T11:09:39", "published_display": "02 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax to present LEVEL trial data at ESC Congress before August results", "summary": "Tenax Therapeutics (Nasdaq: TENX) will present Phase 3 LEVEL clinical trial results at the ESC Congress 2026 in Munich, Germany, on August 29, 2026. The trial focuses on TNX-103 (oral levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-H", "url": "https://www.stocktitan.net/news/TENX/tenax-therapeutics-announces-late-breaking-presentation-of-level-gwp2avnebee4.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:09:39", "published_display": "02 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax lures three new hires with 160,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQWGZZNXpVb3E4WHpBdlhSTDRfMF9xUTJnSTFwY0U5XzdvbjNMZ2FJZ0o0TXV4b1FmbVFncHkyWmJTaDdUR3RfeVVoX00zdVVNR0trSEVGcUNuME9uLXlIUHRZNElsOE1aYkNGdVJEWWR4NVJOSU0xU2FjbE4wQjJONHZrNTFDcjVRc290cXFwQUthOGh0QTF5NjJRTTVIaXVDbDYxa1AzV2Z5T3g4dHFuaE5KeHdIVlBQcnFaS3RJTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax and Orion Secure Long-Term Levosimendan Supply Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOYlB2WXdOMDRXNjg3czd2dXEwaG9YdnZhU1Z6aTdZb0g4dFIyc2w5Y1B3QjRmWjZrVmN5NFZVSzhQMDM1dDcycGFQcGlqei12VlNyTDZ6cjR6SzFLYTRTUGdlTmt3ZVg4cy1YZGlmNVVKTWxONXFBR2hSMnZzZkVoeVVxaHdpOTZuOTVqT0N5ZVlpNmx4UmtQTjlCaWdkS3FwdW9sQko5OGRRaTktbGVZWkhJUXc3YmozSHdNWG1jMWFFcVZudEFpako4SUcxbGw2OEdtdnlTR0hMZw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (NASDAQ: TENX) deepens Orion deal, extends approval deadline to 2035", "summary": "Tenax Therapeutics has entered into a new Supply Agreement with Orion Corporation, making Orion responsible for manufacturing and supplying Tenax\u2019s orally administered levosimendan product for development and commercial use. Concurrently, the companies signed a Sixth Amendment to", "url": "https://www.stocktitan.net/sec-filings/TENX/8-k-tenax-therapeutics-inc-reports-material-event-ad68258dbd6d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T06:10:34", "published_display": "01 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Extends Us Regulatory Approval Deadline To December 31, 2035 Via Sixth Amendment To Orion License - SEC Filing", "summary": "Tenax Therapeutics has extended its US regulatory approval deadline to December 31, 2035. This extension was made possible through the Sixth Amendment to its Orion License. The information was disclosed in an SEC filing.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN432122:0-tenax-therapeutics-extends-us-regulatory-approval-deadline-to-december-31-2035-via-sixth-amendment-to-orion-license-sec-filing/", "source_name": "TradingView", "published_at": "2026-07-01T06:10:34", "published_display": "01 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035, through the sixth amendment to its licensing agreement with Orion.", "summary": "Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035. This extension was facilitated through the sixth amendment to its licensing agreement with Orion. The postponement has been officially filed with the U.S. Securities and Exchange", "url": "https://www.bitget.com/amp/news/detail/12560605484278", "source_name": "Bitget", "published_at": "2026-06-30T21:10:34", "published_display": "30 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (TENX) expands executive and employee severance, CIC plans", "summary": "Tenax Therapeutics has expanded its executive and employee severance and change in control (CIC) plans. The company's Board approved amendments to employment agreements for Christopher Giordano, Thomas Staab, and Stuart Rich, aligning their severance and equity vesting protection", "url": "https://www.stocktitan.net/sec-filings/TENX/8-k-tenax-therapeutics-inc-reports-material-event-d755b1a90273.html", "source_name": "Stock Titan", "published_at": "2026-06-30T06:09:30", "published_display": "30 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell Small Cap Comp Value Benchmark", "summary": "Tenax Therapeutics, Inc. (NasdaqCM:TENX), a pharmaceutical company specializing in cardiovascular and pulmonary diseases, has been added to the Russell Small Cap Comp Value Benchmark. The company's stock price saw a 4.96% increase, and it was also recently included in several oth", "url": "https://www.marketscreener.com/news/tenax-therapeutics-inc-nasdaqcm-tenx-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfde8ff42c", "source_name": "marketscreener.com", "published_at": "2026-06-29T18:10:42", "published_display": "29 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 3000E Index", "summary": "Tenax Therapeutics, Inc. (NasdaqCM: TENX), a pharmaceutical company specializing in cardiovascular and pulmonary diseases, has been included in the Russell 3000E Index. This news follows several other Russell index inclusions for the company, such as the Russell 2000, Russell Mic", "url": "https://www.marketscreener.com/news/tenax-therapeutics-inc-nasdaqcm-tenx-added-to-russell-3000e-index-ce7f5fdedd8cff2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:11:10", "published_display": "29 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc. Actuals & Estimates (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNOVZiLVRzOVN0d0RRaC1UcjlaQzFsNllIOEs2U18wUDU0ejRuQWR1VlZLYlVpU1RRbGtqdFRRWTA0c1pTVVdGZHRBZzJXZ3ktcGQ5X0FfVGNnWVJxSE43YzZGUGU3bk4tMHlPOUxpM2ZPREVMWUZBNTVXaG90N2JDVlMtdTF0UQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T08:31:09+00:00", "published_display": "26 Jun 2026 08:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Initiates Tenax Therapeutics at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-initiates-tenax-therapeutics-buy-102616421.html", "source_name": "MT Newswires", "published_at": "2026-06-22T10:26:16+00:00", "published_display": "22 Jun 2026 10:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Inc (TENX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFBTdGxUTmEwb0hNSVJUaktRS0NBQ21kQTRFX0RkREJPMHR5bEZGdzVhU21scVFROVhCODRYeVliS3c4eGxubzRsZEY0Y0J2ZEZJNzdZRFY3SDdVLVFOUG9IakdxYmZmdVN5TUQxdUMybU10aXJrbmtV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T02:51:57+00:00", "published_display": "17 Jun 2026 02:51", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Tenax Therapeutics stock rating ahead of trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOampPLUttejBaTWtZUjVNakhyVll6cUYtMVZfOHJIc0ROdGwzcUN3cFJsdHdmRlhHZ0RKOWUxeGdRMHJBNVBJRXI4OHZBejN1U3dFWXpzamtCejZVaWp2RUFqVnAzckV6bXQxTnZ6NWtqeGZQX3FlMGwyenlsWlhkTzd6U3I2TmVrZjh4MXE3ekhBV1pNcU5EMERrZFN6bXJKakhFNXpDRmxFaWc5bjQ3ZmRIRTRKTHdLSHdkX0lfTEl5NklxWWR2V3NuZw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tenax Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-q1-earnings-snapshot-110753698.html", "source_name": "Associated Press", "published_at": "2026-05-12T11:07:53+00:00", "published_display": "12 May 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxNNjRKOE1jYzZ2THZWb2dYZnRpQmszSHp3RzF4d0hvTWl0NkEtVzl1LWpwSzJVOFRka2JWM29aSWxTcW1WRFJaai1kU2VCZGJlUUdHTHBLbFlXcndmWWVhQnJDZklWZnZMUlZRZW1lelV1ZW5BWGNjYUk2ZlhOdE5ON1RFTkZKS3E1eWszNWJPN2p5ellzYkFDSmY4MnVWRUNCQ3BtMGoyVEdUblNweWRKSTllMUNRZERScWgwc1VqeUVpTkJ4eG82S1U1Mkk2WEtKQ2d6T2dtYlFVSzBRSlh0MnZ1ZXREMEtVd01rWlZFNXNmVzNIWFZsSGRvdFlYZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPZHZhakRwTlZjamxhTzVFN1JNRVg1UFp5UC1YU29TNEphTmUyczhHR3JJLXNGWU5VOWFzeDBPTXN6QmxJa0NxYkZMaks0UWgtQW9pU2hVWkMxYmJvX3FudzJENk5SQzk1RGw1eWFTbWNVOEpneXY4WVFMN1ZEbHowcXpWTlJWbERUMExtSVRROS11RncwWkE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-appoints-timothy-healey-110000622.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T11:00:00+00:00", "published_display": "04 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tenax Therapeutics Names Thomas Staab as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-names-thomas-staab-125051857.html", "source_name": "MT Newswires", "published_at": "2026-04-22T12:50:51+00:00", "published_display": "22 Apr 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-appoints-thomas-r-110000668.html", "source_name": "GlobeNewswire", "published_at": "2026-04-22T11:00:00+00:00", "published_display": "22 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPa05lYi0wbVozTkMzX3JJTU8xdGtNVVFnTU9KQjBVTG5pZmxCX2lZckF3dTdfUDZpVlFfSlptYTdhNnJxUmo5VUM3YllQNk1HN01nS1BYOEM1UnJNdjRZRWNZV0JzMDIwRmc0QlN5alNaa3FpUU9NOEducTZxU0I2SXdtY1NhNnQ3aUY3WHU2ckY4ZXN1dEo0SUdVb2dYM1Rkc3FmaW1YNzg?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPa281NWtXVUlKUk5IS3NYQ0ZwZDhrZXBGQ0NWVzRTSzFBLWFqV3ZOOFRUQzlNWlQwd0tfOU43RGVVakpORDdmRmxfM0ZuU1J2VHVJaV9LTHJZV2FYczdBZ1RUUFk1RWJOQ0FtTHRwZTdka1g3akVySnVPQVcyMVVYTHVmNm1ORlV6Ml81a0FTT3Q4SThkZWJzZ29QOXExWTlq?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOLVp2eE5CQUlnYlQxWVVKTXZHeFdlYTNHY2xBMUR0R1pPU09pbE9jQ0JEMktRWlBSaURBODdOUUQzcE9PNEdzaHdHREw2dklwc0p3X3NCZ0tYNkJhQVd4VmRqdXZPWlRsTmVDZkdPREhuTExaYm1NNmZfQS1PR29GNXphZ0g3QzkxQ194QjVmUUk1RXIyUkw2c3dQdE9KMTBGZ2pFc01GM0JyS2toTFJjVzEyMVlsYmJpVkNaWHl0WjhaTlBCaEJES0MtdXhBUXRZ?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Stock: A Speculative Buy (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNREZaSGhEZXVObHE5U0hNdWxaTnllakpiUldZM1lWMGhCZlBlcFhSN01YemVTVU1hWUdGd19DUVdlczdhLVp2VkU2N2oyQ2pqaWFyWm5OeEZMZkVETXo0MmgtWFZaOWE3eEpHd0Vqd3hBNVpfa0lQcHdTYkwtTVEtWWJEUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWTZKRzBISGoyZXdXR1IzbjI2b0FybjJvV3Q2aGtGYUxzY1FlZ0llNXBpeExMMGdlb1MwX0Zwcjl2N3Fjb0JBVWEzWXBGSDZfUXdUWHdVSkQ2dXdlTDNkN3dRWm5zYzN3YmZvc0FkWGFKR1dRT3RucHROMXFBYlhlOXg0NzV3SUwwMkd3VjlkNUw4czBwdVZ5MzVIUHJkRWtPUG83cjZ0dHJuaERI?oc=5", "source_name": "Investing News Network", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (TENX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9EcWdsLWhwNUx4RzlVYnJvamNqaF9Od0FIOWZaQjhXdnFiU0RvQ1pwaUltVkMyVUFpWnNtcm9Zb3BVS21td3lHdUxOWGZmT0ZMZmEw?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:10:21+00:00", "published_display": "25 Apr 2025 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Closing of $100 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxNb0tEZl9MSXR5OVExUEl0aC1tMkc3VGxTTkxhWGJZWE1OemFWdXRqWC1UanVzbXY5RkNycnZtQ0FGWkRiX0VxZ0EtUnJPQmd3TmxaMXowUGpEZjgwMjJGbzZQZVN6YTNaNFB0RGJsMjBXMmtzMTdpWE1JYjdvUHdHSE84YXhJalZsSXdyUXotWlprZnNGWFg0aWpJMTNMR2pRbXlvb0QxSGZJS2RhMkFXNi1JdTk3MUI4WXRKN0t0WDE1UU8tQzJGYlBsdmFIWDNRWU1CMjQwcllrWlBjMTRWMlBQcnJYN25WbU9ZSU9JU0F3R05ORlpqZXVkQ3dsci1kRERLQ1RyWnN1X1M3UXVBR0FzSUtJT08zanpaY09nS2gxNElneWxrMW5ybw?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-08-12T07:00:00+00:00", "published_display": "12 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPN0pfT2FJQTdJRkdtdWFpTExhNGtyVW0wdHY3QTNxT3lCVnJzZVNVUTFOekVSa2plRnluejFZNFozZ29Ib09Dend5VWE0bXoxWlZjSHk5ZGhPdk13MFlQd29oRWF6M3dQa1dmMG53Z0lWNmh0NFU2aG95dm5ZZW5ScWVOZjdjcUpBNFNHbWpEUjhrWUlsWkkwdVp0VnZRMXJsYUJvYVNPWmhrRDM2SHB3dVM0NzUtcGMyb2hwZmNxNjljdWRINkNLTWpic1Y0b1JnVW1sMlFqTmdwVktZYVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-08-06T07:00:00+00:00", "published_display": "06 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Appoints Christopher T. Giordano as CEO", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNQW0yWlREb2YwODR6OEZSZGFrZEktbWFYVlBpYVdHcXgyQ1RsMXNHMTJlUGlEUUZJV3RGOEZ3SnNvWWctTDJ2V012aC1LSnZ4Q01DNXRQcTJtMlhraFZOS1Zuamd6am9NX0x6b1I1WWc4MlBJTUZ0azZFMXloZEVYWHljWjJ6anNFaGo3ZE1NTUQyQnRrSzBSem40UQ?oc=5", "source_name": "citybiz", "published_at": "2021-07-07T07:00:00+00:00", "published_display": "07 Jul 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "FMR LLC's Strategic Acquisition of Tenax Therapeutics Inc Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNnA0dXg0RjhtXzV3bEljWHJ4UW1jMkVaYzdzQjY3OEMwZFdnZnJDRnZaSjJFQ2JCUlpNaG5MUmplRTdhSmlZd01zT3Fjaml4LWVWNFlmZjRtclNYa2dhb09uNmNjZmpwLWJfV1NaOUNfbUFZcDNKVVNtWXd1NlZwSHVHU0FuaHRtdHVqenVHVzM4T0dReVlMMmlsaS1tVEVqSjNEdHRDbEl5X1V3Q1NZamFpQlI?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T03:48:59+00:00", "published_display": "15 Jul 2026 03:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tenax Therapeutics Inc For: 14 July By Investing.com", "summary": "This article reports on a Form 4 filing for Tenax Therapeutics Inc. dated July 14. It highlights the stock symbol TENX, which experienced a -2.63% change, and was published by Investing.com.", "url": "https://za.investing.com/news/stock-market-news/form-4-tenax-therapeutics-inc-for-14-july-93CH-4369080", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T00:11:48", "published_display": "15 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (TENX) CEO exercises options, adds 8,719 shares", "summary": "Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026, acquiring 8,719 common shares. These shares were purchased at exercise prices of $5.94 and $3.549 per share, with the aggregate exercise price paid in cash. Following these transact", "url": "https://www.stocktitan.net/sec-filings/TENX/form-4-tenax-therapeutics-inc-insider-trading-activity-2a1ba5559b93.html", "source_name": "Stock Titan", "published_at": "2026-07-14T23:11:48", "published_display": "14 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(TENX) as a Liquidity Pulse for Institutional Tactics", "summary": "An AI model analysis by Stock Traders Daily indicates a strong overweight bias for Tenax Therapeutics Inc. (NASDAQ: TENX) due to strong sentiment across all horizons and a mid-channel oscillation pattern. The analysis highlights an exceptional 89.3:1 risk-reward setup, targeting ", "url": "https://news.stocktradersdaily.com/news_release/8/TENX_as_a_Liquidity_Pulse_for_Institutional_Tactics_071326050001_1783976401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T16:41:36", "published_display": "13 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 3.94M-share holding in Tenax Therapeutics (TENX)", "summary": "FMR LLC has reported a 14.9% stake in Tenax Therapeutics (TENX), owning 3,942,373 shares of common stock as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The filing also notes sole dispositive power over these shares and re", "url": "https://www.stocktitan.net/sec-filings/TENX/schedule-13g-tenax-therapeutics-inc-passive-investment-disclosure-5-2b7f77a60e68.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:39:36", "published_display": "08 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "The article focuses on the enterprise value to EBITDA forward for Tenax Therapeutics, Inc. (NASDAQ: TENX). It presents a financial metric from TradingView, indicating a key valuation ratio for the company without providing specific numerical data. The content primarily serves as ", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T23:11:00", "published_display": "07 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "This page from TradingView provides financial information for Tenax Therapeutics, Inc. (NASDAQ: TENX), specifically focusing on its price to earnings forward. The content indicates market and financial data, but the core numerical values are not displayed in this excerpt.", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:11:06", "published_display": "07 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Raises Target Price to $35", "summary": "LifeSci Capital has maintained its \"Buy\" rating for Tenax Therapeutics (TENX.US) and increased its target price from $27 to $35. Analyst Gaurav Maini, who has a 100% success rate and a 31.8% average return over the past year, made this adjustment. This information is provided by ", "url": "https://www.moomoo.com/news/post/72517777/lifesci-capital-maintains-tenax-therapeutics-tenxus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-06T12:41:29", "published_display": "06 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "This article displays financial data for Tenax Therapeutics, Inc. (NASDAQ: TENX), specifically focusing on its \"Price to sales forward\" metric. The content provides a snapshot of the company's financials and general market information through a TradingView interface.", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T12:41:27", "published_display": "06 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUTBjWWQtREtieFBiTWJZSERmOVNzYmVIRjI5Yk41dkU0TktWd0FHX2NkS3kydEMxSkF5eFc5WDVxR3hfdC1UVWtYaHhvdGVSbmRvemxRZnY2NU1QSjVKdmlNVnUzVjNMWEZmN1pJNkJVV2d1dDRvWGJ3c2VuT3c0TlZ2ZVJ2VWdYTnBDTzN5dDZOQjVJWmp1aDZuSE54YmFfcS1XNmFJQTFpa3d4cjAwNGRR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tenax Therapeutics, Inc. \u2013 NASDAQ:TENX", "summary": "The article provides a title indicating an analysis of Tenax Therapeutics, Inc.'s enterprise value to EBIT forward. However, the content primarily consists of navigation links, market data disclaimers, and website information from TradingView, rather than a substantive financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-TENX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:11:39", "published_display": "06 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tenax Therapeutics, Inc. \u2013 LS:A3EVQN", "summary": "This page provides financial data on Tenax Therapeutics, Inc. (A3EVQN), specifically focusing on its price-to-sales forward ratio. The content indicates that the market was closed at the time of viewing, with no trades reported. It also details the various data providers and copy", "url": "https://www.tradingview.com/symbols/LS-A3EVQN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T18:10:35", "published_display": "05 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Tenax Therapeutics announced inducement option awards on July 1, 2026, to three new non-executive employees in various roles, granting them non-qualified stock options to purchase 160,000 shares. These awards, approved by the Compensation Committee, serve as material inducements ", "url": "https://finance.yahoo.com/healthcare/articles/tenax-therapeutics-announces-inducement-grants-200500596.html?.tsrc=rss", "source_name": "Market source", "published_at": "2026-07-03T08:41:29", "published_display": "03 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Is Maintained at Buy by Chardan Capital", "summary": "Chardan Capital has reiterated its Buy rating on Tenax Therapeutics (NASDAQ: TENX). The article does not provide a price target or an updated analysis, only confirming the maintenance of the rating.", "url": "https://www.moomoo.com/news/post/72402119/tenax-therapeutics-is-maintained-at-buy-by-chardan-capital?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T19:10:53", "published_display": "02 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026", "summary": "Tenax Therapeutics (Nasdaq: TENX) has announced that results from its Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich. The company expects to report topline LEVEL result", "url": "https://investingnews.com/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-data-at-esc-congress-2026/", "source_name": "Investing News Network", "published_at": "2026-07-02T16:11:10", "published_display": "02 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Late-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial data", "summary": "Tenax Therapeutics (TENX) announced that results from its Phase 3 LEVEL clinical trial for TNX-103 in pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) will be presented at the European Society of Cardiology Congress 2026 as a Late-Breaking Clini", "url": "https://www.stocktitan.net/sec-filings/TENX/8-k-tenax-therapeutics-inc-reports-material-event-3dd8bcf66d9d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:09:39", "published_display": "02 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc. (TENX) announced that the data report from one of its pivotal clinical trials has been selected as a late-breaking presentation at the 2026 European Society of Cardiology Congress.", "summary": "Tenax Therapeutics, Inc. (TENX) announced that a data report from one of its pivotal clinical trials has been selected as a late-breaking presentation at the 2026 European Society of Cardiology Congress. This selection indicates international recognition of the company's progress", "url": "https://www.bitget.com/amp/news/detail/12560605487149", "source_name": "Bitget", "published_at": "2026-07-02T11:09:39", "published_display": "02 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax to present LEVEL trial data at ESC Congress before August results", "summary": "Tenax Therapeutics (Nasdaq: TENX) will present Phase 3 LEVEL clinical trial results at the ESC Congress 2026 in Munich, Germany, on August 29, 2026. The trial focuses on TNX-103 (oral levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-H", "url": "https://www.stocktitan.net/news/TENX/tenax-therapeutics-announces-late-breaking-presentation-of-level-gwp2avnebee4.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:09:39", "published_display": "02 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax lures three new hires with 160,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQWGZZNXpVb3E4WHpBdlhSTDRfMF9xUTJnSTFwY0U5XzdvbjNMZ2FJZ0o0TXV4b1FmbVFncHkyWmJTaDdUR3RfeVVoX00zdVVNR0trSEVGcUNuME9uLXlIUHRZNElsOE1aYkNGdVJEWWR4NVJOSU0xU2FjbE4wQjJONHZrNTFDcjVRc290cXFwQUthOGh0QTF5NjJRTTVIaXVDbDYxa1AzV2Z5T3g4dHFuaE5KeHdIVlBQcnFaS3RJTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax and Orion Secure Long-Term Levosimendan Supply Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOYlB2WXdOMDRXNjg3czd2dXEwaG9YdnZhU1Z6aTdZb0g4dFIyc2w5Y1B3QjRmWjZrVmN5NFZVSzhQMDM1dDcycGFQcGlqei12VlNyTDZ6cjR6SzFLYTRTUGdlTmt3ZVg4cy1YZGlmNVVKTWxONXFBR2hSMnZzZkVoeVVxaHdpOTZuOTVqT0N5ZVlpNmx4UmtQTjlCaWdkS3FwdW9sQko5OGRRaTktbGVZWkhJUXc3YmozSHdNWG1jMWFFcVZudEFpako4SUcxbGw2OEdtdnlTR0hMZw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (NASDAQ: TENX) deepens Orion deal, extends approval deadline to 2035", "summary": "Tenax Therapeutics has entered into a new Supply Agreement with Orion Corporation, making Orion responsible for manufacturing and supplying Tenax\u2019s orally administered levosimendan product for development and commercial use. Concurrently, the companies signed a Sixth Amendment to", "url": "https://www.stocktitan.net/sec-filings/TENX/8-k-tenax-therapeutics-inc-reports-material-event-ad68258dbd6d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T06:10:34", "published_display": "01 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Extends Us Regulatory Approval Deadline To December 31, 2035 Via Sixth Amendment To Orion License - SEC Filing", "summary": "Tenax Therapeutics has extended its US regulatory approval deadline to December 31, 2035. This extension was made possible through the Sixth Amendment to its Orion License. The information was disclosed in an SEC filing.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN432122:0-tenax-therapeutics-extends-us-regulatory-approval-deadline-to-december-31-2035-via-sixth-amendment-to-orion-license-sec-filing/", "source_name": "TradingView", "published_at": "2026-07-01T06:10:34", "published_display": "01 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035, through the sixth amendment to its licensing agreement with Orion.", "summary": "Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035. This extension was facilitated through the sixth amendment to its licensing agreement with Orion. The postponement has been officially filed with the U.S. Securities and Exchange", "url": "https://www.bitget.com/amp/news/detail/12560605484278", "source_name": "Bitget", "published_at": "2026-06-30T21:10:34", "published_display": "30 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (TENX) expands executive and employee severance, CIC plans", "summary": "Tenax Therapeutics has expanded its executive and employee severance and change in control (CIC) plans. The company's Board approved amendments to employment agreements for Christopher Giordano, Thomas Staab, and Stuart Rich, aligning their severance and equity vesting protection", "url": "https://www.stocktitan.net/sec-filings/TENX/8-k-tenax-therapeutics-inc-reports-material-event-d755b1a90273.html", "source_name": "Stock Titan", "published_at": "2026-06-30T06:09:30", "published_display": "30 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell Small Cap Comp Value Benchmark", "summary": "Tenax Therapeutics, Inc. (NasdaqCM:TENX), a pharmaceutical company specializing in cardiovascular and pulmonary diseases, has been added to the Russell Small Cap Comp Value Benchmark. The company's stock price saw a 4.96% increase, and it was also recently included in several oth", "url": "https://www.marketscreener.com/news/tenax-therapeutics-inc-nasdaqcm-tenx-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfde8ff42c", "source_name": "marketscreener.com", "published_at": "2026-06-29T18:10:42", "published_display": "29 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 3000E Index", "summary": "Tenax Therapeutics, Inc. (NasdaqCM: TENX), a pharmaceutical company specializing in cardiovascular and pulmonary diseases, has been included in the Russell 3000E Index. This news follows several other Russell index inclusions for the company, such as the Russell 2000, Russell Mic", "url": "https://www.marketscreener.com/news/tenax-therapeutics-inc-nasdaqcm-tenx-added-to-russell-3000e-index-ce7f5fdedd8cff2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:11:10", "published_display": "29 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics, Inc. Actuals & Estimates (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNOVZiLVRzOVN0d0RRaC1UcjlaQzFsNllIOEs2U18wUDU0ejRuQWR1VlZLYlVpU1RRbGtqdFRRWTA0c1pTVVdGZHRBZzJXZ3ktcGQ5X0FfVGNnWVJxSE43YzZGUGU3bk4tMHlPOUxpM2ZPREVMWUZBNTVXaG90N2JDVlMtdTF0UQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T08:31:09+00:00", "published_display": "26 Jun 2026 08:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Initiates Tenax Therapeutics at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-initiates-tenax-therapeutics-buy-102616421.html", "source_name": "MT Newswires", "published_at": "2026-06-22T10:26:16+00:00", "published_display": "22 Jun 2026 10:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Inc (TENX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFBTdGxUTmEwb0hNSVJUaktRS0NBQ21kQTRFX0RkREJPMHR5bEZGdzVhU21scVFROVhCODRYeVliS3c4eGxubzRsZEY0Y0J2ZEZJNzdZRFY3SDdVLVFOUG9IakdxYmZmdVN5TUQxdUMybU10aXJrbmtV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T02:51:57+00:00", "published_display": "17 Jun 2026 02:51", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Tenax Therapeutics stock rating ahead of trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOampPLUttejBaTWtZUjVNakhyVll6cUYtMVZfOHJIc0ROdGwzcUN3cFJsdHdmRlhHZ0RKOWUxeGdRMHJBNVBJRXI4OHZBejN1U3dFWXpzamtCejZVaWp2RUFqVnAzckV6bXQxTnZ6NWtqeGZQX3FlMGwyenlsWlhkTzd6U3I2TmVrZjh4MXE3ekhBV1pNcU5EMERrZFN6bXJKakhFNXpDRmxFaWc5bjQ3ZmRIRTRKTHdLSHdkX0lfTEl5NklxWWR2V3NuZw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-q1-earnings-snapshot-110753698.html", "source_name": "Associated Press", "published_at": "2026-05-12T11:07:53+00:00", "published_display": "12 May 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxNNjRKOE1jYzZ2THZWb2dYZnRpQmszSHp3RzF4d0hvTWl0NkEtVzl1LWpwSzJVOFRka2JWM29aSWxTcW1WRFJaai1kU2VCZGJlUUdHTHBLbFlXcndmWWVhQnJDZklWZnZMUlZRZW1lelV1ZW5BWGNjYUk2ZlhOdE5ON1RFTkZKS3E1eWszNWJPN2p5ellzYkFDSmY4MnVWRUNCQ3BtMGoyVEdUblNweWRKSTllMUNRZERScWgwc1VqeUVpTkJ4eG82S1U1Mkk2WEtKQ2d6T2dtYlFVSzBRSlh0MnZ1ZXREMEtVd01rWlZFNXNmVzNIWFZsSGRvdFlYZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPZHZhakRwTlZjamxhTzVFN1JNRVg1UFp5UC1YU29TNEphTmUyczhHR3JJLXNGWU5VOWFzeDBPTXN6QmxJa0NxYkZMaks0UWgtQW9pU2hVWkMxYmJvX3FudzJENk5SQzk1RGw1eWFTbWNVOEpneXY4WVFMN1ZEbHowcXpWTlJWbERUMExtSVRROS11RncwWkE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-appoints-timothy-healey-110000622.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T11:00:00+00:00", "published_display": "04 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Names Thomas Staab as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-names-thomas-staab-125051857.html", "source_name": "MT Newswires", "published_at": "2026-04-22T12:50:51+00:00", "published_display": "22 Apr 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tenax-therapeutics-appoints-thomas-r-110000668.html", "source_name": "GlobeNewswire", "published_at": "2026-04-22T11:00:00+00:00", "published_display": "22 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPa05lYi0wbVozTkMzX3JJTU8xdGtNVVFnTU9KQjBVTG5pZmxCX2lZckF3dTdfUDZpVlFfSlptYTdhNnJxUmo5VUM3YllQNk1HN01nS1BYOEM1UnJNdjRZRWNZV0JzMDIwRmc0QlN5alNaa3FpUU9NOEducTZxU0I2SXdtY1NhNnQ3aUY3WHU2ckY4ZXN1dEo0SUdVb2dYM1Rkc3FmaW1YNzg?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPa281NWtXVUlKUk5IS3NYQ0ZwZDhrZXBGQ0NWVzRTSzFBLWFqV3ZOOFRUQzlNWlQwd0tfOU43RGVVakpORDdmRmxfM0ZuU1J2VHVJaV9LTHJZV2FYczdBZ1RUUFk1RWJOQ0FtTHRwZTdka1g3akVySnVPQVcyMVVYTHVmNm1ORlV6Ml81a0FTT3Q4SThkZWJzZ29QOXExWTlq?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOLVp2eE5CQUlnYlQxWVVKTXZHeFdlYTNHY2xBMUR0R1pPU09pbE9jQ0JEMktRWlBSaURBODdOUUQzcE9PNEdzaHdHREw2dklwc0p3X3NCZ0tYNkJhQVd4VmRqdXZPWlRsTmVDZkdPREhuTExaYm1NNmZfQS1PR29GNXphZ0g3QzkxQ194QjVmUUk1RXIyUkw2c3dQdE9KMTBGZ2pFc01GM0JyS2toTFJjVzEyMVlsYmJpVkNaWHl0WjhaTlBCaEJES0MtdXhBUXRZ?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Stock: A Speculative Buy (NASDAQ:TENX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNREZaSGhEZXVObHE5U0hNdWxaTnllakpiUldZM1lWMGhCZlBlcFhSN01YemVTVU1hWUdGd19DUVdlczdhLVp2VkU2N2oyQ2pqaWFyWm5OeEZMZkVETXo0MmgtWFZaOWE3eEpHd0Vqd3hBNVpfa0lQcHdTYkwtTVEtWWJEUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWTZKRzBISGoyZXdXR1IzbjI2b0FybjJvV3Q2aGtGYUxzY1FlZ0llNXBpeExMMGdlb1MwX0Zwcjl2N3Fjb0JBVWEzWXBGSDZfUXdUWHdVSkQ2dXdlTDNkN3dRWm5zYzN3YmZvc0FkWGFKR1dRT3RucHROMXFBYlhlOXg0NzV3SUwwMkd3VjlkNUw4czBwdVZ5MzVIUHJkRWtPUG83cjZ0dHJuaERI?oc=5", "source_name": "Investing News Network", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics (TENX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9EcWdsLWhwNUx4RzlVYnJvamNqaF9Od0FIOWZaQjhXdnFiU0RvQ1pwaUltVkMyVUFpWnNtcm9Zb3BVS21td3lHdUxOWGZmT0ZMZmEw?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:10:21+00:00", "published_display": "25 Apr 2025 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Closing of $100 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxNb0tEZl9MSXR5OVExUEl0aC1tMkc3VGxTTkxhWGJZWE1OemFWdXRqWC1UanVzbXY5RkNycnZtQ0FGWkRiX0VxZ0EtUnJPQmd3TmxaMXowUGpEZjgwMjJGbzZQZVN6YTNaNFB0RGJsMjBXMmtzMTdpWE1JYjdvUHdHSE84YXhJalZsSXdyUXotWlprZnNGWFg0aWpJMTNMR2pRbXlvb0QxSGZJS2RhMkFXNi1JdTk3MUI4WXRKN0t0WDE1UU8tQzJGYlBsdmFIWDNRWU1CMjQwcllrWlBjMTRWMlBQcnJYN25WbU9ZSU9JU0F3R05ORlpqZXVkQ3dsci1kRERLQ1RyWnN1X1M3UXVBR0FzSUtJT08zanpaY09nS2gxNElneWxrMW5ybw?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-08-12T07:00:00+00:00", "published_display": "12 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPN0pfT2FJQTdJRkdtdWFpTExhNGtyVW0wdHY3QTNxT3lCVnJzZVNVUTFOekVSa2plRnluejFZNFozZ29Ib09Dend5VWE0bXoxWlZjSHk5ZGhPdk13MFlQd29oRWF6M3dQa1dmMG53Z0lWNmh0NFU2aG95dm5ZZW5ScWVOZjdjcUpBNFNHbWpEUjhrWUlsWkkwdVp0VnZRMXJsYUJvYVNPWmhrRDM2SHB3dVM0NzUtcGMyb2hwZmNxNjljdWRINkNLTWpic1Y0b1JnVW1sMlFqTmdwVktZYVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-08-06T07:00:00+00:00", "published_display": "06 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenax Therapeutics Appoints Christopher T. Giordano as CEO", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNQW0yWlREb2YwODR6OEZSZGFrZEktbWFYVlBpYVdHcXgyQ1RsMXNHMTJlUGlEUUZJV3RGOEZ3SnNvWWctTDJ2V012aC1LSnZ4Q01DNXRQcTJtMlhraFZOS1Zuamd6am9NX0x6b1I1WWc4MlBJTUZ0azZFMXloZEVYWHljWjJ6anNFaGo3ZE1NTUQyQnRrSzBSem40UQ?oc=5", "source_name": "citybiz", "published_at": "2021-07-07T07:00:00+00:00", "published_display": "07 Jul 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 54, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 35, "score": 55, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.9, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.05, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 17.55, "latest_week": "2026-07-10", "one_week_move": 13.5, "four_week_move": 52.9, "twelve_week_move": 21.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.313633, "market_dynamics_buy_signal": false, "relative_strength": 43.193062, "fair_value_gap": 76.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.6611, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+13.5% over one week, +52.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 5}, {"label": "Seeking Alpha", "count": 3}, {"label": "Investing News Network", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+13.5% over one week, +52.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "FMR LLC's Strategic Acquisition of Tenax Therapeutics Inc Shares"}], "updated_at": "2026-07-16T10:55:34.133964+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}